Medicines reimbursement savings in 2017 and Finnish risk-sharing model regarding reimbursable medicines
The budgeted cut in medicines reimbursement expenses payable from the national health insurance is 10% in 2017. The cuts will amount to 134 million euros, constituting one element in the overall savings in public spending, targeted at core areas of the Finnish society.
Savings measure based on price competition of biological medicines and biosimilars
One of the main savings measures related to the medicines reimbursement expenditure in 2017 is the promotion of the price competition of biological medicines and biosimilars. The patents of many innovative original biological medicines currently in use in the Finnish outpatient care and included in the respective medicines reimbursement system will expire in the next few years. This will potentially lead to the entry of their biosimilars in the Finnish market, with the ensuing price competition.
Reference group initiated by parallel import and parallel distribution products
On 1 April 2017 parallel import and parallel distribution products will initiate a reference price group with the respective on-patent or off-patent original product.
Finland will introduce risk-sharing agreements in the medicines reimbursement system
As of the beginning of 2017, there will be a new risk-sharing agreement related to the outpatient medicines reimbursable through the health insurance, the so-called conditional reimbursability system.
The Finnish Medicines Verification System takes a leap forward
In December 2016, the pharmaceutical supply chain actors will form the Finnish Medicines Verification Organisation FiMVO (Suomen Lääkevarmennus Oy in Finnish). The organization will take charge of implementing the verification system according to the requirements of the Falsified Medicines Directive (FMD).